<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00604435</url>
  </required_header>
  <id_info>
    <org_study_id>Endostar B-01</org_study_id>
    <secondary_id>XOBCR01</secondary_id>
    <nct_id>NCT00604435</nct_id>
  </id_info>
  <brief_title>Neoadjuvant Endostatin and Chemotherapy for Breast Cancer</brief_title>
  <official_title>Phase II Trial of Neoadjuvant Recombinant Human Endostatin, Docetaxel and Epirubicin as First-line Therapy in Patients With Breast Cancer</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Xijing Hospital</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Xijing Hospital</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This study was designed to determine the efficacy and safety of neoadjuvant docetaxel and
      epirubicin (DE) with or without human recombinant endostatin (endostar) for breast cancer
      patients. The hypothesis of this protocol is that a combined angiogenesis inhibiting therapy
      to chemotherapy could further enhance the cytotoxic activity in breast cancer.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This is an open labelled, prospective, randomized, phase II clinical trial. A total of 60
      patients with core-biopsy confirmed breast cancer, stage ⅡA to ⅢC, and to be treated with
      neoadjuvant systemic therapy are eligible for entry into this study. Patients will be
      allocated randomly to two groups to receive either 3 cycles of neoadjuvant DE and endostar or
      3 cycles of neoadjuvant DE. All cases receive mammography, contrast-enhanced ultrasound
      (CEUS), magnetic resonance angiography (MRA), and positron emission tomography (PET) scanning
      pre- and post-neoadjuvant therapy, and then undergo surgical resection. The primary endpoint
      is clinical/pathological response. The secondary endpoint is (1) the safety and tolerability
      of the regimens, (2) the role of mammography, CEUS, MRA and PET for response evaluation, and
      (3) angiogenic profile and biological information involved in tumor response.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>February 2008</start_date>
  <completion_date type="Actual">January 2010</completion_date>
  <primary_completion_date type="Actual">January 2010</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Single (Participant)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>clinical/pathological response</measure>
    <time_frame>one year</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>safety and tolerability</measure>
    <time_frame>one year</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">69</enrollment>
  <condition>Breast Cancer</condition>
  <arm_group>
    <arm_group_label>chemotherapy</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>neoadjuvant therapy with 3 cycles of Docetaxel and Epirubicin</description>
  </arm_group>
  <arm_group>
    <arm_group_label>chemotherapy plus endostatin</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>neoadjuvant therapy with 3 cycles of Docetaxel and Epirubicin plus endostatin</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>docetaxel and epirubicin</intervention_name>
    <description>docetaxel 75mg/m2, IV (in the vein) on day 1 of each 21 day cycle; epirubicin 60 mg/m2, IV (in the vein) on day 1 of each 21 day cycle, totally 3 cycles</description>
    <arm_group_label>chemotherapy</arm_group_label>
    <other_name>docetaxel, Sanofi-Aventis</other_name>
    <other_name>epirubicin, Pfizer</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>docetaxel and epirubicin plus endostatin</intervention_name>
    <description>docetaxel 75mg/m2, IV (in the vein) on day 1 of each 21 day cycle; epirubicin 60 mg/m2, IV (in the vein) on day 1 of each 21 day cycle; endostatin 7.5mg/m2, IV (in the vein) on 1st to 14th days of each 21 day cycle; every 3 weeks, totally 3 cycles</description>
    <arm_group_label>chemotherapy plus endostatin</arm_group_label>
    <other_name>recombinant human endostatin, Simcere Co. China</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Histologically confirmed invasive breast cancer (core needle biopsy for breast cancer
             diagnosis and fine needle aspiration for lymph node metastasis diagnosis)

          -  Stage ⅡA-ⅢC

          -  Age 18-70

          -  ECOG performance status 0-2

          -  No evidence of distant metastasis

          -  No previous therapy

          -  Normal hematologic function

          -  left ventricular ejection fraction greater than 50 percent

          -  No abnormality of renal or liver function

          -  Written informed consent

        Exclusion Criteria:

          -  With allergic constitution or possible allergic reflection to drugs to be used in this
             study

          -  Any concurrent uncontrolled medical or psychiatric disorder

          -  History of severe heart diseases, including congestive heart failure, unstable angina,
             uncontrolled arrhythmia, myocardial infarction, uncontrolled high blood pressure, or
             heart valve disease.

          -  History of bleeding diathesis

          -  Being pregnant or nursing
      </textblock>
    </criteria>
    <gender>Female</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>70 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Ling Wang, MD</last_name>
    <role>Study Director</role>
    <affiliation>Fourth Military Medical University</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Jianghao Chen, MD, PhD</last_name>
    <role>Study Chair</role>
    <affiliation>Fourth Military Medical University</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Xijing Hospital, Fourth Military Medical University</name>
      <address>
        <city>Xi'an</city>
        <state>Shaanxi</state>
        <zip>710032</zip>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>China</country>
  </location_countries>
  <link>
    <url>http://www.springerlink.com/content/v5187707r0517w39/fulltext.pdf</url>
    <description>By far, endostatin has not been used for the treatment of breast cancer patients in either adjuvant or neoadjuvant settings. This article reported endostatin gene therapy enhances the efficacy of taxane to suppress breast cancer and metastases in mice.</description>
  </link>
  <reference>
    <citation>Li J, Dong X, Xu Z, Jiang X, Jiang H, Krissansen GW, Sun X. Endostatin gene therapy enhances the efficacy of paclitaxel to suppress breast cancers and metastases in mice. J Biomed Sci. 2008 Jan;15(1):99-109. Epub 2007 Aug 18.</citation>
    <PMID>17705027</PMID>
  </reference>
  <verification_date>January 2010</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>January 16, 2008</study_first_submitted>
  <study_first_submitted_qc>January 29, 2008</study_first_submitted_qc>
  <study_first_posted type="Estimate">January 30, 2008</study_first_posted>
  <last_update_submitted>January 18, 2010</last_update_submitted>
  <last_update_submitted_qc>January 18, 2010</last_update_submitted_qc>
  <last_update_posted type="Estimate">January 20, 2010</last_update_posted>
  <responsible_party>
    <name_title>Dai-Ming Fan, Principal of Fourth Military Medical University</name_title>
    <organization>Fourth Military Medical University</organization>
  </responsible_party>
  <keyword>breast cancer</keyword>
  <keyword>neoadjuvant chemotherapy</keyword>
  <keyword>docetaxel</keyword>
  <keyword>epirubicin</keyword>
  <keyword>recombinant human endostatin (endostar)</keyword>
  <keyword>chemotherapy</keyword>
  <keyword>endostatin</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Breast Neoplasms</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Docetaxel</mesh_term>
    <mesh_term>Epirubicin</mesh_term>
    <mesh_term>Endostatins</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

